2006 OPEN FORUM Abstracts
Peri-Operative Administration of Aerosolized Prostacyclin via Face Mask and Endotracheal Intubation in a Patient with Severe Pulmonary Hypertension
Mark
Siobal BS RRT, Robin Stackhouse MD, Jean-Francois Pittet MD, Julin Tang MD MS,
Department of Anesthesia,
Introduction: Aerosolized
prostacyclin (AP) can be an effective treatment for pulmonary hypertension (PH)
in the acute care setiing.1 AP selectively dilates pulmonary
vasculature, reduces pulmonary arterial pressure (PAP), decreases pulmonary
vascular resistance and afterload to the right ventricle (RV). In the
peri-operative setting, AP can be effective in preventing RV failure.
Case Summary: A 61 year old female
admitted for shortness of breath and pneumonia was found to have large
bilateral ovarian tumors and scheduled for an exploratory laparatomy. The
patient's pre-operative workup was significant for severe COPD and cor
pulmonale with baseline ABG 7.42, 53, 48, 28.0, 9.3 , FEV1 = 25%,
FEF 25/75 = 5%, DLCO = 20% of predicted; and severe PH with reduced RV systolic
function and an estimated systolic PAP of 75 mmHg by transthoracic
echocardiogram. During pre-op assessment, the anesthetic plan was to administer
aerosolized prostacyclin intra-operatively to prevent worsening RV function. In
the operating room prior to intubation and general anesthesia, a pulmonary
artery catheter (Edwards Lifesciences,
Discussion: This case report
demonstrates the effectiveness of utilizing this delivery system for
aerosolized prostacyclin2 by face mask and by endotracheal
intubation during the peri-operative period in a patient with significant RV
dysfunction. Inhalation of the alkaline aerosol (approximate pH of 10.5)2
did not cause bronchospasm in this patient with chronic airway obstruction. We
conclude that AP can be an effective treatment in high risk patients with
severe PH and RV dysfunction in the acute care, critical care, and intra‑operative
setting.
| PAP (mean) mmHg | Pre AP 60/33 (41) | Post AP 42/28 (33) | IntraOp AP 43/28 (33)* | ICU AP 42/25 (31)* | PostExtub AP 43/24 (30) | AP Off 64/33 (43)* |
| CCO L/min | 2.3 | 4.7 | 5.5 * | 5.2* | 5.8 | 6.2* |
| RV EF % | 10 | 22 | --- | 24* | 20 | 21* |
| RVEDV mL | 387 | 276 | --- | 272* | 313 | 359* |
*
average of several recorded measurements
1. Siobal MS. Aerosolized Prostacyclins. Resp
Care 2004;49(6): 640-652.
2. Siobal MS, Kallet RH, Pittet JF, Warnecke
EL, Kraemer RW, Venkayya RV, Tang JF. Description and evaluation of a delivery
system for aerosolized prostacyclin Resp Care 2003;48(8):742-753.